Sulfasalazine-induced angioimmunoblastic lymphadenopathy developing in a patient with juvenile chronic arthritis.
We describe a patient with juvenile chronic arthritis who developed reactive angioimmunoblastic lymphadenopathy, induced by sulfasalazine. Development of angioimmunoblastic lymphadenopathy although rare, is a very serious side effect of sulfasalazine treatment, and patients treated with this drug should be watched carefully.
Pay
S
S
GATA Romatoloji Bilim Dah, Etlik, Ankara, Turkey. isimsek1@yahoo.com
Dinc
A
A
Simsek
I
I
Can
C
C
Erdem
H
H
D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001171:Arthritis, Juvenile / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D002738:Chloroquine / Q000633:toxicity; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D012460:Sulfasalazine / Q000009:adverse effects*
D018501:Antirheumatic Agents; D012460:Sulfasalazine; D002738:Chloroquine; D008775:Methylprednisolone; D008727:Methotrexate